Prockop Darwin J, Oh Joo Youn, Lee Ryang Hwa
Institute for Regenerative Medicine, College of Medicine, Texas A&M University, 1114 TAMU, 206 Olsen Boulevard, College Station, TX 77845, USA.
Department of Ophthalmology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea; Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea.
Mol Ther. 2017 Aug 2;25(8):1748-1756. doi: 10.1016/j.ymthe.2017.06.004. Epub 2017 Jun 22.
Much of what we know about immunology suggests that little is to be gained from experiments in which human cells are administered to immunocompetent mice. Multiple reports have demonstrated that this common assumption does not hold for experiments with human mesenchymal stem/stromal cells (hMSCs). The data demonstrate that hMSCs can suppress immune responses to a variety of stimuli in immunocompetent mice by a range of different mechanisms that are similar to those employed by mouse MSCs. Therefore, further experiments with hMSCs in mice will make it possible to generate preclinical data that will improve both the efficacy and safety of the clinical trials with the cells that are now in progress.
我们对免疫学的诸多了解表明，将人类细胞注入具有免疫活性的小鼠体内的实验收获甚微。多项报告表明，这一普遍假设在人类间充质干细胞（hMSCs）实验中并不成立。数据表明，hMSCs可通过一系列与小鼠MSCs所采用机制相似的不同机制，抑制具有免疫活性的小鼠对多种刺激的免疫反应。因此，在小鼠中对hMSCs进行进一步实验将有可能生成临床前数据，从而提高目前正在进行的细胞临床试验的疗效和安全性。
